Literature DB >> 19409437

Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.

Wing-Sai Chan1, Siva Sundara Kumar Durairajan, Jia-Hong Lu, Yan Wang, Li-Xia Xie, Wan-Fung Kum, Irene Koo, Ken Kin Lam Yung, Min Li.   

Abstract

Parkinson's disease (PD) is caused by a progressive degeneration of dopaminergic neurons in the substantia nigra. Oxidative stress and neural degeneration are suggested to be involved in the pathogenesis of Parkinson's disease. In the present study, Astragaloside IV (AS-IV) extracted from the dried root of Astragalus membranaceus, a well-known Chinese medicine used for the treatment of neurodegenerative diseases, was investigated for its capacity to protect dopaminergic neurons in experimental Parkinson's disease. By examining the effect of AS-IV on 6-hydroxydopamine (6-OHDA)-induced loss of dopaminergic neurons in primary nigral culture, we found that AS-IV pretreatment significantly and dose-dependently attenuated 6-OHDA-induced loss of dopaminergic neurons. Neuronal fiber length studies showed that massive neuronal cell death with degenerated neurons was observed in those cultures incubated with 6-OHDA, whereas in AS-IV co-treatments most dopaminergic neurons were seen to be intact and sprouting. In flow cytometric analysis, AS-IV resulted in a marked and dose-dependent rescue in tyrosine hydrolase (TH)-immunopositive cells from 6-OHDA-induced degeneration of dopaminergic neurons. Double immunofluorescence revealed that AS-IV treatment alone at concentrations of 100 and 200 microM increased the level of TH and NOS (nitrite oxide synthase) immunoreactivities; however, the protective effect of AS-IV on TH and NOS immunopositive cells in 6-OHDA treated nigral cell cultures was only seen at a concentration of 100 microM. These findings show that AS-IV can protect dopaminergic neurons against 6-OHDA-induced degeneration. Besides the neuroprotective effect, AS-IV alone promoted neurite outgrowth and increased TH and NOS immunoreactive of dopaminergic neurons. The neuroprotective and neurosprouting effects of AS-IV are specific for dopaminergic neurons and it has therapeutic potential in the treatment of PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409437     DOI: 10.1016/j.neuint.2009.04.012

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  23 in total

1.  Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production.

Authors:  Zhi-Guo Zhang; Lin Wu; Ju-Lei Wang; Jian-Dong Yang; Jing Zhang; Jian Zhang; Li-Hong Li; Yi Xia; Li-Bo Yao; Huai-Zhou Qin; Guo-Dong Gao
Journal:  Mol Cell Biochem       Date:  2012-01-26       Impact factor: 3.396

2.  Protective effects of Astragaloside IV against oxidative injury and apoptosis in cultured astrocytes by regulating Nrf2/JNK signaling.

Authors:  Jintao Yang; Chongyu Shao; Wentao Li; Haitong Wan; Yu He; Jiehong Yang
Journal:  Exp Brain Res       Date:  2021-04-08       Impact factor: 1.972

3.  Astragaloside IV and echinacoside benefit neuronal properties via direct effects and through upregulation of SOD1 astrocyte function in vitro.

Authors:  Yang Tian; Shijie Jin; Vanessa Promes; Xuemei Liu; Yunling Zhang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-20       Impact factor: 3.000

Review 4.  Advances in neuroprotective ingredients of medicinal herbs by using cellular and animal models of Parkinson's disease.

Authors:  Sandeep Vasant More; Hemant Kumar; Seong Mook Kang; Soo-Yeol Song; Kippeum Lee; Dong-Kug Choi
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-01       Impact factor: 2.629

5.  Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels.

Authors:  Yixin He; Min Du; Yan Gao; Hongshuai Liu; Hongwei Wang; Xiaojun Wu; Zhengtao Wang
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

6.  Protective effects of astragaloside IV against amyloid beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening.

Authors:  Qinru Sun; Ning Jia; Weixi Wang; Hui Jin; Jiehua Xu; Haitao Hu
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

7.  Astragaloside IV ameliorates renal injury in db/db mice.

Authors:  Huili Sun; Wenjing Wang; Pengxun Han; Mumin Shao; Gaofeng Song; Heng Du; Tiegang Yi; Shunmin Li
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

8.  Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts.

Authors:  Zhen-Fei Wang; Da-Guang Ma; Zhe Zhu; Yong-Ping Mu; Yong-Yan Yang; Li Feng; Hao Yang; Jun-Qing Liang; Yong-Yan Liu; Li Liu; Hai-Wen Lu
Journal:  World J Gastroenterol       Date:  2017-12-28       Impact factor: 5.742

9.  EGCG Protects against 6-OHDA-Induced Neurotoxicity in a Cell Culture Model.

Authors:  Dan Chen; Anumantha G Kanthasamy; Manju B Reddy
Journal:  Parkinsons Dis       Date:  2015-12-06

10.  The mechanism of astragaloside IV promoting sciatic nerve regeneration.

Authors:  Xiaohong Zhang; Jiajun Chen
Journal:  Neural Regen Res       Date:  2013-08-25       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.